Evidence map›Paper›PMID 36589262›Full record

ArticleTransplant international : official journal of the European Society for Organ Transplantation2022

Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation: A Single Center Experience of 196 Patients Over 30 Years.

Vibeke K J Vergote, Christophe M Deroose, Steffen Fieuws, Wim Laleman, Ben Sprangers, Anne Uyttebroeck, Johan Van Cleemput, Gregor Verhoef, Robin Vos, Thomas Tousseyn and 1 more

Open access · goldAbstract read
In one paragraph

Article in Transplant international : official journal of the European Society for Organ Transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Prevention of OncogenicTransplant international : official journal of the European Society for Organ Transplantation · 2023
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Vibeke K J VergoteDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Christophe M DerooseDepartment of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
Steffen FieuwsInteruniversity Institute for Biostatistics and Statistical Bioinformatics, KU Leuven-University of Leuven, Leuven, Belgium.
Wim LalemanDepartment of Liver and Biliopancreatic Disorders, University Hospitals Leuven, Leuven, Belgium.
Ben SprangersLaboratory of Molecular Immunology, Department of Microbiology, Immunology and Transplantation, Rega Institute, KU Leuven, Leuven, Belgium.
Anne UyttebroeckDepartment of Pediatric Hemato-Oncology, Department of Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Johan Van CleemputDepartment of Cardiology, University Hospitals Leuven, Leuven, Belgium.
Gregor VerhoefDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Robin VosDepartment of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Thomas TousseynDepartment of Pathology, University Hospitals Leuven, Leuven, Belgium.
Daan DierickxDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
KU Leuven · BEStatistics Belgium · BEVIB-UAntwerp Center for Molecular Neurology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a rare but life-threatening complication after transplantation. In this retrospective, monocentric study we aimed to collect real life data regarding PTLD and determine the role of Epstein Barr Virus (EBV) status and year of diagnosis on prognosis. We identified 196 biopsy-proven PTLD after solid organ transplantation (SOT) diagnosed at the University Hospitals Leuven (Belgium) from 1989 to 2019. EBV status was positive in 61% of PTLD. The median overall survival (OS) was 5.7 years (95% CI: 2.99-11.1). Although EBV positivity was not significantly correlated with OS in multivariate analyses (HR: 1.44 (95% CI: 0.93-2.24);

Indexed as

Epstein-Barr Virus InfectionsLymphoproliferative DisordersOrgan TransplantationHerpesvirus 4, HumanHumansRetrospective StudiesepidemiologyEpstein Barr Virusoutcomepost-transplant lymphoproliferative disorderprognosistransplantation

Identifiers

PMID36589262
PMCPMC9794588
OpenAlexW4311313050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.